Corporate Satellite Symposia Schedule
Schedule is subject to change. Times are listed in Eastern Time (EDT).
Thursday, May 5
7:30–8:30 AM
Revolutionizing the Standard of NF1 Care: Managing NF1-Associated PNs, Treatment-Related Toxicities, and Future Implications with Novel MEK Inhibitors
CME Breakfast Symposium (Oncology Topic)
Register to attend in person or virtually at PeerView.com/NF22-Live.
This CME symposium is supported by Alexion Pharmaceuticals, Inc.
12:45-1:45 PM
Transfusional Iron Overload: Informing Clinical Management with Biology
Non-CME Lunch Symposium (Hematology Topic)
Speakers:
Tom Coates, MD
Keck School of Medicine
University of Southern California
Janet Kwiatkowski, MD
Children’s Hospital of Philadelphia
This non-CME symposium is supported by Chiesi Global Rare Diseases.
12:45-1:45 PM
Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy & the Role of Novel Asparaginase Compounds
CME Lunch Symposium (Oncology Topic)
Register to attend in person or virtually at PeerView.com/ALLPed22-Live.
This CME symposium is supported by Jazz Pharmaceuticals, Inc.
6:15-6:45 PM
Discussion on the Impact of Hemolysis and Anemia on the Organ Damage in Sickle Cell Disease
Please join us to learn about sickle cell disease (SCD) as we discuss complications that patients with SCD battle from childhood through adulthood. We will also discuss the underlying pathophysiology of SCD.
Speaker:
Nirmish Shah, MD
Duke University School of Medicine
Durham, NC
This education theater is supported by Global Blood Therapeutics, Inc.
Friday, May 6
7:30–8:30 AM
Strategies for Optimizing Iron Chelation in Sickle Cell Disease Management from Pediatric Through Adult Care
Non-CME Breakfast Symposium (Hematology Topic)
Speaker:
Sharif M. Badawy, MD, MS
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, IL
This non-CME symposium is supported by Chiesi Global Rare Diseases.
8:15–8:45 AM
The Clinical Role of VITRAKVI1: Presentation on NTRK Gene Fusions in Pediatric Cancer
Speaker:
Caroline Hastings, MD
Director, Pediatric Hematology Oncology Fellowship Program, Pediatric NeuroOncology
Pediatric Hematology Oncology Department - Children's Hospital & Research Center Oakland
Professor of Pediatrics - University of California, San Francisco School of Medicine
This education theater is supported by Bayer.
10:45–11:15 AM
Discussion in the Treatment of Sickle Cell Disease, Moving Beyond Pain as a Primary Target
Please join us to learn about the underlying pathophysiology of sickle cell disease. We will discuss the pathology of red blood cells sickling, and how this leads to subsequent hemolysis, anemia, and vaso-occlusions. This program will also review the clinical efficacy and safety of the first and only FDA-approved hemoglobin polymerization inhibitor for patients 4 years and older.
Speaker:
Richard Drachtman, MD
Rutgers Cancer Institute of New Jersey
Newark, NJ
This education theater is supported by Global Blood Therapeutics, Inc.
12:40–1:10 PM
Gaucher Disease: An Opportunity to Recognize and Diagnosis Patients for Pediatric Hematologists
Please join us to learn about the underlying pathophysiology of sickle cell disease. We will discuss the pathology of red blood cells sickling, and how this leads to subsequent hemolysis, anemia, and vaso-occlusions. This program will also review the clinical efficacy and safety of the first and only FDA-approved hemoglobin polymerization inhibitor for patients 4 years and older.
Speaker:
Joel Weinthal, MD
Texas Oncology Pediatrics
Medical City Children’s Hospital
Dallas, TX
This education theater is supported by Takeda.
12:45-1:45 PM
Physician-Led Presentation of Patient Cases with Neurofibromatosis Type 1 (NF1)
Non-CME Lunch Symposium (Oncology Topic)
Speaker:
Kelly Vallance, MD, MPH
Cook Children’s Medical Center
Fort Worth, TX
This non-CME symposium is supported by Alexion Pharmaceuticals, Inc.
12:45-1:45 PM
The Only Recombinant Erwinia Asparaginase Approved For The Treatment Of ALL/LBL
Non-CME Lunch Symposium (Hematology Topic)
Learning Objectives:
- The importance of asparaginase as a foundational component of Acute Lymphoblastic Leukemia (ALL) treatment and the clinical impact of hypersensitivity reactions
- Clinical information for an ALL treatment, including the study overview, efficacy data, dosing schedule, and safety profile
Speaker:
Scott Howard, MD, MSc
University of Tennessee Health Science Center (UTHSC)
Memphis, TN
This non-CME symposium is supported by Jazz Pharmaceuticals, Inc.
1:20–1:50 PM
Use of the Karius Test for Diagnosing Critical Infections in Pediatric Patients
This education theater is supported by Karius, Inc.